2021
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow DB, Bhalla S, Beasley MB, Sholl LM, Kerr KM, Gnjatic S, Wistuba II, Rimm DL, Tsao MS, Hirsch FR. PD-L1 as a biomarker of response to immune-checkpoint inhibitors. Nature Reviews Clinical Oncology 2021, 18: 345-362. PMID: 33580222, DOI: 10.1038/s41571-021-00473-5.Peer-Reviewed Original ResearchConceptsImmune checkpoint inhibitorsSelection of patientsPD-L1L1 antibodyImmunohistochemistry assaysPD-L1 immunohistochemistry assaysOutcomes of patientsBiomarkers of responseCompanion diagnostic assayTypes of cancerPD-1Clinical outcomesSelection biomarkerProspective comparisonClinical challengeNew therapiesFuture treatmentPatientsSolid tumorsClinical useSpecific agentsInter-assay variabilityBiomarkersCurrent roleDiagnostic assays
2020
A Biomarker for Predicting Responsiveness to Stem Cell Therapy Based on Mechanism-of-Action: Evidence from Cerebral Injury
Hartman R, Nathan N, Ghosh N, Pernia C, Law J, Nuryyev R, Plaia A, Yusof A, Tone B, Dulcich M, Wakeman D, Dilmac N, Niles W, Sidman R, Obenaus A, Snyder E, Ashwal S. A Biomarker for Predicting Responsiveness to Stem Cell Therapy Based on Mechanism-of-Action: Evidence from Cerebral Injury. Cell Reports 2020, 31: 107622. PMID: 32402283, DOI: 10.1016/j.celrep.2020.107622.Peer-Reviewed Original ResearchConceptsHuman neural stem cellsHypoxic-ischemic injuryTherapeutic mechanismCerebral hypoxic-ischemic injuryCell therapyMolecular profileHierarchical region splittingStem cell therapyNeural stem cellsCerebral injurySelection biomarkerPredicting ResponsivenessNecrotic coreCognitive outcomesBiomarkersTherapyInjuryLesionsStem cellsResponsivenessPenumbraCellsCore volumeSalvageabilityRecipients
2019
Assessment of tumor mutation burden calculation from gene panel sequencing data
Xu Z, Dai J, Wang D, Lu H, Dai H, Ye H, Gu J, Chen S, Huang B. Assessment of tumor mutation burden calculation from gene panel sequencing data. OncoTargets And Therapy 2019, 12: 3401-3409. PMID: 31123404, PMCID: PMC6510391, DOI: 10.2147/ott.s196638.Peer-Reviewed Original ResearchTumor mutation burdenNon-small cell lung cancerHigh tumor mutation burdenImmune checkpoint blockadeCell lung cancerCancer Genome AtlasCheckpoint blockadeLung cancerClinical trialsSelection biomarkerMutation burdenCancer typesWhole-exome sequencing dataGenome AtlasPanel sequencing dataTargeted sequencingClinical applicationExome sequencing dataBurden calculationsWhole-genome sequencingMutation levelsSomatic mutation data
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply